Verastem to Announce Q4 Earnings on March 4
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 23 hours ago
0mins
Should l Buy VSTM?
Source: seekingalpha
- Earnings Announcement: Verastem is set to release its Q4 2023 earnings on March 4 after market close, with a consensus EPS estimate of -$0.50, reflecting a 16.7% year-over-year improvement, indicating potential financial performance recovery.
- Revenue Expectations: Analysts project Verastem's Q4 revenue to reach $16.84 million, suggesting a degree of stability and growth potential in the market despite ongoing challenges.
- Historical Performance Review: Over the past two years, Verastem has beaten EPS estimates 63% of the time and revenue estimates 25% of the time, indicating a relatively reliable performance in financial forecasting that may influence investor confidence.
- Clinical Trial Updates: Following setbacks with the RAMP-203 project, Verastem has downgraded its rating to Buy and plans to provide clinical updates in 2026, demonstrating the company's proactive approach to seeking future growth opportunities despite current challenges.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy VSTM?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on VSTM
Wall Street analysts forecast VSTM stock price to rise
6 Analyst Rating
6 Buy
0 Hold
0 Sell
Strong Buy
Current: 5.680
Low
14.00
Averages
15.60
High
20.00
Current: 5.680
Low
14.00
Averages
15.60
High
20.00
About VSTM
Verastem, Inc. is a late-stage development biopharmaceutical company, which focuses on the development and commercialization of new medicines to improve the lives of patients diagnosed with ras sarcoma (RAS)/ mitogen-activated pathway kinase (MAPK) pathway-driven cancers. Its product candidates include avutometinib and defactinib. Avutometinib is an oral RAF/MEK clamp that inhibits MEK1/2 kinase activities and induces inactive complexes of MEK with A-Raf proto-oncogene, potentially serine/threonine kinase (ARAF), B-Raf proto-oncogene serine/threonine kinase (BRAF) and C-raf proto-oncogene serine/threonine kinase, creating antitumor response through maximal RAS/MAPK pathway inhibition. Defactinib is an oral, selective inhibitor of FAK and proline-rich tyrosine kinase (PYK2), the two members of the focal adhesion kinase family of non-receptor protein tyrosine kinases. FAK and PYK2 integrate signals from integrin and growth factor receptors to regulate cell proliferation.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Verastem to Announce Q4 Earnings on March 4
- Earnings Announcement: Verastem is set to release its Q4 2023 earnings on March 4 after market close, with a consensus EPS estimate of -$0.50, reflecting a 16.7% year-over-year improvement, indicating potential financial performance recovery.
- Revenue Expectations: Analysts project Verastem's Q4 revenue to reach $16.84 million, suggesting a degree of stability and growth potential in the market despite ongoing challenges.
- Historical Performance Review: Over the past two years, Verastem has beaten EPS estimates 63% of the time and revenue estimates 25% of the time, indicating a relatively reliable performance in financial forecasting that may influence investor confidence.
- Clinical Trial Updates: Following setbacks with the RAMP-203 project, Verastem has downgraded its rating to Buy and plans to provide clinical updates in 2026, demonstrating the company's proactive approach to seeking future growth opportunities despite current challenges.
See More
Verastem Q4 Earnings Beat Expectations
- Earnings Highlights: Verastem reported a Q4 GAAP EPS of -$0.50, beating expectations by $0.02, indicating a slight improvement in financial performance despite remaining in a loss position.
- Revenue Growth: The company achieved Q4 revenue of $17.54 million, exceeding market expectations by $0.7 million, suggesting an increase in product acceptance in the market, which could lay the groundwork for future growth.
- Clinical Developments: Verastem plans clinical updates in 2026, and despite setbacks with RAMP-203 targeting KRAS G12C NSCLC, the commitment to ongoing R&D may influence investor confidence positively.
- Rating Adjustment: Following the RAMP-203 setback, Verastem's rating has been downgraded to “Buy,” which may impact short-term stock performance but could also present an entry opportunity for long-term investors.
See More
Verastem Oncology to Host Q4 2025 Financial Results Call
- Conference Call Announcement: Verastem Oncology will host a conference call on March 4, 2026, at 4:30 PM ET to discuss its Q4 and full-year 2025 financial results, aiming to provide investors with insights into its latest business developments and financial performance.
- Access Instructions: Investors can dial (888) 596-4144 for U.S. access or (646) 968-2525 for international calls, entering passcode 7321921 at least 10 minutes prior to the start time to ensure smooth participation in this important financial update.
- Live Webcast and Replay: The call will be available via a live audio webcast on the company's investor website, accompanied by slides, and a replay will be archived post-event, allowing investors who cannot attend live to access the information.
- Company Overview: Verastem Oncology focuses on developing new medicines for RAS/MAPK pathway-driven cancers, with products like AVMAPKI™ and FAKZYNJA™ CO-PACK already in the market, showcasing the company's innovative capabilities in the biopharmaceutical sector.
See More
Verastem Oncology Schedules Q4 2025 Financial Results Call
- Conference Call Announcement: Verastem Oncology will host a conference call on March 4, 2026, at 4:30 PM ET to discuss its Q4 and full-year 2025 financial results, reflecting the company's commitment to transparency and investor communication.
- Access Details: Investors can dial (888) 596-4144 for U.S. access or (646) 968-2525 for international calls, entering passcode 7321921 at least 10 minutes prior to the event, ensuring smooth participation.
- Live Webcast and Replay: The call will be available via a live audio webcast on the company's website under the
See More
Verastem Projects $17.5 Million Net Revenue for Q4 2025
- Revenue Expectations: Verastem anticipates net product revenue of approximately $17.5 million for Q4 2025 and about $30.9 million for the full year, based on preliminary unaudited results, primarily driven by sales of AVMAPKI FAKZYNJA CO-PACK following its U.S. approval in May 2025.
- Cash Reserves: As of December 31, 2025, Verastem reported $205 million in cash, cash equivalents, and investments, and on a pro forma basis, including proceeds from outstanding cash warrants, total cash is approximately $234 million, which is expected to fund operations into the first half of 2027.
- Clinical Development: The company plans to continue advancing the clinical development of its oral KRAS G12D inhibitor, VS-7375, and expects to report an interim update from its Phase 1/2 trial in the first half of 2026, which will provide critical data for future product line development.
- Leadership Engagement: Verastem's leadership will participate in a fireside chat at the Guggenheim Emerging Outlook Conference on February 11, which will help enhance the company's visibility among investors and strengthen market engagement.
See More
Verastem Projects $30.9M Revenue for 2025 with Key Product Developments
- 2025 Revenue Outlook: Verastem anticipates net product revenues of approximately $30.9 million for AVMAPKI™ FAKZYNJA™ CO-PACK in 2025, with about $17.5 million expected in Q4, reflecting strong market demand following FDA approval in May 2025, marking a successful transition to a commercial-stage company.
- Strong Cash Position: As of December 31, 2025, Verastem reported cash, cash equivalents, and investments totaling $205 million, with pro forma cash reaching $234 million after warrant exercises, ensuring operational runway into the first half of 2027, indicating robust financial health.
- Accelerated Clinical Development: The company plans to rapidly advance its clinical development of VS-7375, a selective oral KRAS G12D inhibitor, which is expected to demonstrate best-in-class potential across multiple solid tumor indications, further solidifying its competitive edge in oncology.
- Future Strategic Focus: In 2026, Verastem will concentrate on maximizing the commercial launch of AVMAPKI FAKZYNJA CO-PACK while advancing its differentiated pipeline targeting RAS/MAPK pathway-driven cancers, aiming for sustainable long-term growth and self-sustaining commercialization by the second half of 2026.
See More
Verastem to Announce Q4 Earnings on March 4
- Earnings Announcement: Verastem is set to release its Q4 2023 earnings on March 4 after market close, with a consensus EPS estimate of -$0.50, reflecting a 16.7% year-over-year improvement, indicating potential financial performance recovery.
- Revenue Expectations: Analysts project Verastem's Q4 revenue to reach $16.84 million, suggesting a degree of stability and growth potential in the market despite ongoing challenges.
- Historical Performance Review: Over the past two years, Verastem has beaten EPS estimates 63% of the time and revenue estimates 25% of the time, indicating a relatively reliable performance in financial forecasting that may influence investor confidence.
- Clinical Trial Updates: Following setbacks with the RAMP-203 project, Verastem has downgraded its rating to Buy and plans to provide clinical updates in 2026, demonstrating the company's proactive approach to seeking future growth opportunities despite current challenges.
See More
Verastem Q4 Earnings Beat Expectations
- Earnings Highlights: Verastem reported a Q4 GAAP EPS of -$0.50, beating expectations by $0.02, indicating a slight improvement in financial performance despite remaining in a loss position.
- Revenue Growth: The company achieved Q4 revenue of $17.54 million, exceeding market expectations by $0.7 million, suggesting an increase in product acceptance in the market, which could lay the groundwork for future growth.
- Clinical Developments: Verastem plans clinical updates in 2026, and despite setbacks with RAMP-203 targeting KRAS G12C NSCLC, the commitment to ongoing R&D may influence investor confidence positively.
- Rating Adjustment: Following the RAMP-203 setback, Verastem's rating has been downgraded to “Buy,” which may impact short-term stock performance but could also present an entry opportunity for long-term investors.
See More
Verastem Oncology to Host Q4 2025 Financial Results Call
- Conference Call Announcement: Verastem Oncology will host a conference call on March 4, 2026, at 4:30 PM ET to discuss its Q4 and full-year 2025 financial results, aiming to provide investors with insights into its latest business developments and financial performance.
- Access Instructions: Investors can dial (888) 596-4144 for U.S. access or (646) 968-2525 for international calls, entering passcode 7321921 at least 10 minutes prior to the start time to ensure smooth participation in this important financial update.
- Live Webcast and Replay: The call will be available via a live audio webcast on the company's investor website, accompanied by slides, and a replay will be archived post-event, allowing investors who cannot attend live to access the information.
- Company Overview: Verastem Oncology focuses on developing new medicines for RAS/MAPK pathway-driven cancers, with products like AVMAPKI™ and FAKZYNJA™ CO-PACK already in the market, showcasing the company's innovative capabilities in the biopharmaceutical sector.
See More
Verastem Oncology Schedules Q4 2025 Financial Results Call
- Conference Call Announcement: Verastem Oncology will host a conference call on March 4, 2026, at 4:30 PM ET to discuss its Q4 and full-year 2025 financial results, reflecting the company's commitment to transparency and investor communication.
- Access Details: Investors can dial (888) 596-4144 for U.S. access or (646) 968-2525 for international calls, entering passcode 7321921 at least 10 minutes prior to the event, ensuring smooth participation.
- Live Webcast and Replay: The call will be available via a live audio webcast on the company's website under the
See More
Verastem Projects $17.5 Million Net Revenue for Q4 2025
- Revenue Expectations: Verastem anticipates net product revenue of approximately $17.5 million for Q4 2025 and about $30.9 million for the full year, based on preliminary unaudited results, primarily driven by sales of AVMAPKI FAKZYNJA CO-PACK following its U.S. approval in May 2025.
- Cash Reserves: As of December 31, 2025, Verastem reported $205 million in cash, cash equivalents, and investments, and on a pro forma basis, including proceeds from outstanding cash warrants, total cash is approximately $234 million, which is expected to fund operations into the first half of 2027.
- Clinical Development: The company plans to continue advancing the clinical development of its oral KRAS G12D inhibitor, VS-7375, and expects to report an interim update from its Phase 1/2 trial in the first half of 2026, which will provide critical data for future product line development.
- Leadership Engagement: Verastem's leadership will participate in a fireside chat at the Guggenheim Emerging Outlook Conference on February 11, which will help enhance the company's visibility among investors and strengthen market engagement.
See More
Verastem Projects $30.9M Revenue for 2025 with Key Product Developments
- 2025 Revenue Outlook: Verastem anticipates net product revenues of approximately $30.9 million for AVMAPKI™ FAKZYNJA™ CO-PACK in 2025, with about $17.5 million expected in Q4, reflecting strong market demand following FDA approval in May 2025, marking a successful transition to a commercial-stage company.
- Strong Cash Position: As of December 31, 2025, Verastem reported cash, cash equivalents, and investments totaling $205 million, with pro forma cash reaching $234 million after warrant exercises, ensuring operational runway into the first half of 2027, indicating robust financial health.
- Accelerated Clinical Development: The company plans to rapidly advance its clinical development of VS-7375, a selective oral KRAS G12D inhibitor, which is expected to demonstrate best-in-class potential across multiple solid tumor indications, further solidifying its competitive edge in oncology.
- Future Strategic Focus: In 2026, Verastem will concentrate on maximizing the commercial launch of AVMAPKI FAKZYNJA CO-PACK while advancing its differentiated pipeline targeting RAS/MAPK pathway-driven cancers, aiming for sustainable long-term growth and self-sustaining commercialization by the second half of 2026.
See More
